- Home
- FBNC vs IMCR Comparison
FBNC vs IMCR Comparison
Compare FBNC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBNC
- IMCR
- Stock Information
- Founded
- FBNC 1934
- IMCR 2008
- Country
- FBNC United States
- IMCR United Kingdom
- Employees
- FBNC N/A
- IMCR N/A
- Industry
- FBNC Major Banks
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBNC Finance
- IMCR Health Care
- Exchange
- FBNC Nasdaq
- IMCR Nasdaq
- Market Cap
- FBNC 1.7B
- IMCR 1.4B
- IPO Year
- FBNC N/A
- IMCR 2021
- Fundamental
- Price
- FBNC $39.96
- IMCR $29.20
- Analyst Decision
- FBNC Buy
- IMCR Buy
- Analyst Count
- FBNC 3
- IMCR 12
- Target Price
- FBNC $52.00
- IMCR $63.00
- AVG Volume (30 Days)
- FBNC 190.8K
- IMCR 372.8K
- Earning Date
- FBNC 04-23-2025
- IMCR 05-07-2025
- Dividend Yield
- FBNC 2.18%
- IMCR N/A
- EPS Growth
- FBNC N/A
- IMCR N/A
- EPS
- FBNC 1.84
- IMCR N/A
- Revenue
- FBNC $333,724,000.00
- IMCR $310,202,000.00
- Revenue This Year
- FBNC $32.94
- IMCR $18.97
- Revenue Next Year
- FBNC $5.80
- IMCR $8.43
- P/E Ratio
- FBNC $21.87
- IMCR N/A
- Revenue Growth
- FBNC N/A
- IMCR 24.36
- 52 Week Low
- FBNC $29.53
- IMCR $27.19
- 52 Week High
- FBNC $50.34
- IMCR $66.00
- Technical
- Relative Strength Index (RSI)
- FBNC 43.99
- IMCR 49.95
- Support Level
- FBNC $39.73
- IMCR $28.92
- Resistance Level
- FBNC $42.65
- IMCR $30.04
- Average True Range (ATR)
- FBNC 1.17
- IMCR 1.49
- MACD
- FBNC 0.23
- IMCR 0.10
- Stochastic Oscillator
- FBNC 45.02
- IMCR 53.71
About FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing and investment advisory services.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.